- Home
- BDTX vs THTX Comparison
BDTX vs THTX Comparison
Compare BDTX & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- THTX
- Stock Information
- Founded
- BDTX 2014
- THTX 1993
- Country
- BDTX United States
- THTX Canada
- Employees
- BDTX N/A
- THTX N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- THTX Health Care
- Exchange
- BDTX Nasdaq
- THTX Nasdaq
- Market Cap
- BDTX 132.5M
- THTX 119.1M
- IPO Year
- BDTX 2020
- THTX N/A
- Fundamental
- Price
- BDTX $2.58
- THTX $3.16
- Analyst Decision
- BDTX Strong Buy
- THTX Hold
- Analyst Count
- BDTX 6
- THTX 1
- Target Price
- BDTX $14.83
- THTX N/A
- AVG Volume (30 Days)
- BDTX 1.3M
- THTX 656.3K
- Earning Date
- BDTX 08-05-2025
- THTX 07-14-2025
- Dividend Yield
- BDTX N/A
- THTX N/A
- EPS Growth
- BDTX N/A
- THTX N/A
- EPS
- BDTX 0.09
- THTX N/A
- Revenue
- BDTX $70,000,000.00
- THTX $88,666,000.00
- Revenue This Year
- BDTX N/A
- THTX N/A
- Revenue Next Year
- BDTX N/A
- THTX $15.13
- P/E Ratio
- BDTX $29.29
- THTX N/A
- Revenue Growth
- BDTX N/A
- THTX 13.52
- 52 Week Low
- BDTX $1.20
- THTX $1.12
- 52 Week High
- BDTX $6.75
- THTX $3.20
- Technical
- Relative Strength Index (RSI)
- BDTX 60.64
- THTX 75.50
- Support Level
- BDTX $2.43
- THTX $2.28
- Resistance Level
- BDTX $2.72
- THTX $2.62
- Average True Range (ATR)
- BDTX 0.18
- THTX 0.10
- MACD
- BDTX -0.00
- THTX 0.03
- Stochastic Oscillator
- BDTX 76.11
- THTX 94.21
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.